November 3, 2005 – Amgen and Abgenix reported strong data for their colorectal cancer drug, panitumumab; Novartis won FDA approval for Exjade, a treatment for iron overload caused by blood transfusions; Bayer and Onyx Pharma reported good results for sorafenib, their kidney cancer drug; Biogen Idec and Elan said Tysabri showed some success against Crohn’s disease; and Merck won a major victory in its continuing liability troubles stemming from Vioxx. The Centient Biotech 200™ was up 62 points at 3832.06, an impressive percentage increase of 1.64%.
